Cell-based therapy using hepatocytes are highly expected as a curative measure for hemophilia, because both FVIII and FIX are produced in the liver [23–26] and only 1–5% of increase in plasma FVIII (or FIX) activity levels can dramatically improve the bleeding symptom of hemophilia patients [27]. Here, F8 is linked to hemophilia.